Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  monoclonal antibody conjugate
Results 1-25 of 1404 for your search:
Start Over
Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: M14-467, NCI-2015-01096, 2014-002609-39, NCT02462525
A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: M14-237, NCI-2014-00926, 2014-003154-14, NCT02099058
Chimeric Fibril-Reactive Monoclonal Antibody 111F4 in Treating Patients with Relapsed or Refractory Amyloid Light-Chain Amyloidosis
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and over
Trial IDs: AAAM5108, NCI-2014-01515, IRB-AAAM5108, NCT02245867
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan and Evaluation of Combination DCDS4501A and Obinutuzumab in Patients With Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO27834, NCI-2013-00539, 2011-004377-84, NCT01691898
A Safety Study of SGN-LIV1A in Breast Cancer Patients
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SGNLVA-001, NCI-2013-02245, NCT01969643
Glembatumumab Vedotin in Treating Patients with Recurrent or Refractory Osteosarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 49 years
Trial IDs: AOST1521, NCI-2015-01037, NCT02487979
A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CDX011-05, NCI-2015-00448, NCT02302339
Glembatumumab Vedotin in Treating Patients with Metastatic or Locally Recurrent Uveal Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9855, NCI-2015-00159, NCT02363283
Monoclonal Antibody 3F8 in Treating Patients with High-Risk Neuroblastoma and GD2-Positive Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 1 to 21
Trial IDs: 11-009, NCI-2011-03341, NCT01419834
Brentuximab Vedotin Maintenance after Donor Stem Cell Transplant in Treating Patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: 2013-0351, NCI-2014-01593, NCT02169505
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and 0ver
Trial IDs: IMGN853-0401, NCI-2012-01561, NCT01609556
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29365, NCI-2015-00293, 2014-001361-28, NCT02257567
ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AGS15E-13-1, NCI-2013-02093, NCT01963052
Bevacizumab with or without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients with Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1174, NCI-2012-01989, CDR0000737109, NCCTG-N1174, NCT01648348
Rituximab and Brentuximab Vedotin with Deferred Bone Marrow Transplant in Treating Patients with Hodgkin Lymphoma
Phase: No phase specified
Type: Treatment
Age: 16 and over
Trial IDs: J1354, NCI-2014-02618, NA_00080336, NA_00080336_AM00043510, NA_00080336 / CIR00008874, NA_00080336 / CR00005615, NCT01900496
Monoclonal Antibody Therapy in Treating Younger Patients with Relapsed or Refractory Neuroblastoma, Osteosarcoma, or Melanoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 21
Trial IDs: SJGD2, NCI-2011-01150, ED FDN, NCT00743496
Anti-B7H1 Monoclonal Antibody MEDI4736 in Treating Patients with Locally Advanced or Metastatic Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-109, NCI-2014-02513, NCT02227667
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with Relapsed or Refractory High-Risk Neuroblastoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 1
Trial IDs: 12-230, NCI-2013-00007, NCT01757626
Monoclonal Antibody 3F8 and Aldesleukin in Treating Patients with High-Risk Neuroblastoma and Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months and over
Trial IDs: 12-116, NCI-2012-01383, NCT01662804
Humanized Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with Recurrent Osteosarcoma
Phase: Phase II
Type: Treatment
Age: 2 to 40
Trial IDs: 15-096, NCI-2015-01423, NCT02502786
Monoclonal Antibody Therapy before Stem Cell Transplant in Treating Patients with Relapsed or Refractory Lymphoid Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2361.00, NCI-2012-01505, NCT01678443
Brentuximab Vedotin and Rituximab in Treating Patients with Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 12H09, NCI-2012-03090, STU00072695, NCT01805037
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with High-Risk Neuroblastoma
Phase: No phase specified
Type: Treatment
Age: Not specified
Trial IDs: 13-260, NCI-2014-00815, NCT02100930
Brentuximab Vedotin before Autologous Stem Cell Transplant in Treating Patients with Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 11051, NCI-2011-01135, 117313, NCT01393717
Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 18
Trial IDs: C25002, NCI-2012-01146, 133300410A0384, 2011-001240-29, NL38209.078.11, U1111-1158-2613, NCT01492088
Start Over